Skip to main content
Assets
Eli Lilly and logo
LLY.NYSE
Eli Lilly and
Health Care · Pharmaceuticals

Global pharmaceutical company developing innovative medicines for diabetes, oncology, immunology, and neuroscience including breakthrough weight-loss drugs.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Eli Lilly and.

Historical AI Opinions

Eli Lilly and Company (LLY.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+113.6%

Includes 0.40% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-73.53577.281.23K1.88K2.53KNov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$1,209+9.5%Not Generated this time
$1,324+19.9%Not Generated this time
$1,438+30.2%Not Generated this time
$1,562+41.4%Not Generated this time
$1,682+52.3%Not Generated this time
$1,811+64.0%Not Generated this time
$1,935+75.2%Not Generated this time
$2,066+87.1%Not Generated this time
$2,186+97.9%Not Generated this time
$2,313+109.4%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Eli Lilly maintains its leadership position in the diabetes and obesity markets with Mounjaro and Zepbound, driving strong double-digit revenue growth for the next 3-4 years. Growth gradually moderates as the market matures and competition intensifies. The company successfully scales manufacturing to meet overwhelming demand. The pipeline delivers incremental value, with successful label expansions for existing drugs and approval of at least one new significant product, though a major breakthrough like a highly effective Alzheimer's drug faces mixed success or a slower-than-hoped uptake. The valuation remains elevated but is supported by robust earnings growth, leading to steady, albeit more moderate, share price appreciation over the forecast horizon, reflecting a balance of opportunity and execution risk.

2. Scenarios & Signals

2.1. Bull Case

Eli Lilly's GLP-1 franchise (Mounjaro/Zepbound) exceeds already high expectations, capturing over 60% of the rapidly expanding obesity market due to superior efficacy and successful manufacturing scale-up. Simultaneously, donanemab gains broad approval and achieves blockbuster status in Alzheimer's treatment, a massive untapped market. The oral GLP-1 candidate, orforglipron, demonstrates a best-in-class profile, securing future dominance. Favorable pricing environments persist, and the company executes flawlessly on its pipeline, leading to significant earnings beats and multiple expansion. The market capitalization realistically challenges the largest companies globally, justified by unprecedented growth in major therapeutic areas. This scenario assumes minimal competitive disruption and no major regulatory or safety setbacks.

2.2. Bear Case

Intensifying competition from Novo Nordisk's next-generation drugs and new entrants erodes Lilly's market share in obesity and diabetes faster than anticipated. Unexpected long-term safety issues with GLP-1 agonists emerge, leading to class-wide regulatory warnings and litigation, severely dampening growth. Concurrently, key pipeline assets, particularly in Alzheimer's and immunology, fail to meet clinical endpoints or gain regulatory approval. Aggressive government price controls on pharmaceuticals are enacted in the U.S., significantly compressing margins. The stock's high valuation proves unsustainable as growth decelerates, leading to a severe multiple contraction and a prolonged period of price stagnation or decline, bringing its market cap more in line with historical pharmaceutical norms.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 532Thinking Tokens: 3,139Response Tokens: 8,168Total Tokens: 11,839
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.